ANTI THYMOCYTE GLOBULIN (RABBIT)

N/A

Manufactured by Genzyme Corporation

15,925 FDA adverse event reports analyzed

Last updated: 2026-04-14

About ANTI THYMOCYTE GLOBULIN (RABBIT)

ANTI THYMOCYTE GLOBULIN (RABBIT) is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Genzyme Corporation. The most commonly reported adverse reactions for ANTI THYMOCYTE GLOBULIN (RABBIT) include PYREXIA, OFF LABEL USE, DRUG INEFFECTIVE, TRANSPLANT REJECTION, CYTOMEGALOVIRUS INFECTION. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ANTI THYMOCYTE GLOBULIN (RABBIT).

Top Adverse Reactions

PYREXIA665 reports
OFF LABEL USE609 reports
DRUG INEFFECTIVE490 reports
TRANSPLANT REJECTION443 reports
CYTOMEGALOVIRUS INFECTION442 reports
FEBRILE NEUTROPENIA321 reports
DIARRHOEA292 reports
THROMBOCYTOPENIA274 reports
SEPSIS265 reports
PNEUMONIA257 reports
ACUTE GRAFT VERSUS HOST DISEASE256 reports
PRODUCT USE IN UNAPPROVED INDICATION256 reports
HYPOTENSION243 reports
ACUTE KIDNEY INJURY241 reports
PANCYTOPENIA230 reports
NEUTROPENIA228 reports
ACUTE GRAFT VERSUS HOST DISEASE IN SKIN221 reports
KIDNEY TRANSPLANT REJECTION217 reports
SERUM SICKNESS217 reports
EPSTEIN BARR VIRUS INFECTION211 reports
BK VIRUS INFECTION209 reports
RENAL IMPAIRMENT208 reports
THROMBOTIC MICROANGIOPATHY208 reports
GRAFT VERSUS HOST DISEASE204 reports
BLOOD CREATININE INCREASED200 reports
POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER196 reports
LEUKOPENIA195 reports
NAUSEA189 reports
CYTOMEGALOVIRUS INFECTION REACTIVATION185 reports
HYPERTENSION180 reports
ANAEMIA179 reports
INFECTION178 reports
RESPIRATORY FAILURE177 reports
CYTOMEGALOVIRUS VIRAEMIA171 reports
CHRONIC GRAFT VERSUS HOST DISEASE168 reports
SEPTIC SHOCK152 reports
URINARY TRACT INFECTION152 reports
VOMITING146 reports
DYSPNOEA145 reports
COMPLICATIONS OF TRANSPLANTED KIDNEY140 reports
CYSTITIS HAEMORRHAGIC140 reports
MULTI ORGAN FAILURE138 reports
PLATELET COUNT DECREASED135 reports
CHILLS134 reports
RENAL FAILURE132 reports
HEART TRANSPLANT REJECTION131 reports
RENAL TUBULAR NECROSIS126 reports
BRONCHOPULMONARY ASPERGILLOSIS125 reports
MULTIPLE ORGAN DYSFUNCTION SYNDROME125 reports
POLYOMAVIRUS ASSOCIATED NEPHROPATHY124 reports
MYELOSUPPRESSION122 reports
TACHYCARDIA121 reports
RESPIRATORY DISTRESS118 reports
EPSTEIN BARR VIRUS ASSOCIATED LYMPHOPROLIFERATIVE DISORDER116 reports
CYTOMEGALOVIRUS TEST POSITIVE115 reports
ACUTE MYELOID LEUKAEMIA RECURRENT112 reports
BACTERAEMIA111 reports
ABDOMINAL PAIN110 reports
PULMONARY OEDEMA110 reports
DEATH108 reports
RASH108 reports
ACUTE RESPIRATORY DISTRESS SYNDROME107 reports
LYMPHADENOPATHY107 reports
TOXICITY TO VARIOUS AGENTS105 reports
DELAYED GRAFT FUNCTION104 reports
ALANINE AMINOTRANSFERASE INCREASED103 reports
WHITE BLOOD CELL COUNT DECREASED103 reports
ACUTE GRAFT VERSUS HOST DISEASE IN INTESTINE99 reports
TRANSPLANT FAILURE99 reports
NEPHROPATHY TOXIC98 reports
BACTERIAL INFECTION97 reports
BONE MARROW FAILURE94 reports
DISEASE RECURRENCE94 reports
EPSTEIN BARR VIRAEMIA94 reports
GRAFT LOSS93 reports
LUNG DISORDER93 reports
STAPHYLOCOCCAL INFECTION93 reports
ARTHRALGIA92 reports
ASPARTATE AMINOTRANSFERASE INCREASED92 reports
MUCOSAL INFLAMMATION91 reports
HEADACHE88 reports
CANDIDA INFECTION87 reports
HAEMOGLOBIN DECREASED87 reports
RENAL FAILURE ACUTE86 reports
ESCHERICHIA INFECTION83 reports
DRUG INTOLERANCE81 reports
ADENOVIRUS INFECTION80 reports
BLOOD BILIRUBIN INCREASED80 reports
DEHYDRATION76 reports
KLEBSIELLA INFECTION75 reports
COVID 1974 reports
GENERALISED OEDEMA74 reports
POLYOMAVIRUS VIRAEMIA74 reports
DECREASED APPETITE73 reports
INFUSION RELATED REACTION73 reports
PNEUMONIA CYTOMEGALOVIRAL73 reports
DRUG INTERACTION72 reports
COUGH71 reports
THERAPEUTIC RESPONSE DECREASED70 reports
ENTEROCOCCAL INFECTION69 reports

Report Outcomes

Out of 7,838 classified reports for ANTI THYMOCYTE GLOBULIN (RABBIT):

Serious 96.6%Non-Serious 3.4%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Male3,592 (56.3%)
Female2,679 (42.0%)
Unknown113 (1.8%)

Reports by Age

Age 53150 reports
Age 60134 reports
Age 52126 reports
Age 9121 reports
Age 43121 reports
Age 56116 reports
Age 55115 reports
Age 57109 reports
Age 50106 reports
Age 58101 reports
Age 61101 reports
Age 4899 reports
Age 6397 reports
Age 5195 reports
Age 3894 reports
Age 4692 reports
Age 1690 reports
Age 5490 reports
Age 6690 reports
Age 2589 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with ANTI THYMOCYTE GLOBULIN (RABBIT)?

This profile reflects 15,925 FDA FAERS reports that mention ANTI THYMOCYTE GLOBULIN (RABBIT). Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for ANTI THYMOCYTE GLOBULIN (RABBIT)?

Frequently reported terms in FAERS include PYREXIA, OFF LABEL USE, DRUG INEFFECTIVE, TRANSPLANT REJECTION, CYTOMEGALOVIRUS INFECTION, FEBRILE NEUTROPENIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures ANTI THYMOCYTE GLOBULIN (RABBIT)?

Labeling and FAERS entries often list Genzyme Corporation in connection with ANTI THYMOCYTE GLOBULIN (RABBIT). Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.